SAIL66, a next generation CLDN6-targeting T-cell engager, demonstrates potent antitumor efficacy through dual binding to CD3/CD137

MLA

Shu Feng, et al. “SAIL66, a next Generation CLDN6-Targeting T-Cell Engager, Demonstrates Potent Antitumor Efficacy through Dual Binding to CD3/CD137.” Journal for ImmunoTherapy of Cancer, vol. 12, no. 10, Oct. 2024. EBSCOhost, https://doi.org/10.1136/jitc-2024-009563.

APA

Shu Feng, Hiroyuki Aburatani, Mika Kamata-Sakurai, Shinya Ishii, Takayuki Kamikawa, Naoki Kimura, Masaru Muraoka, Kenji Taniguchi, Ryo Uchikawa, Moe Yoshimoto, Sho Akai, Tatsushi Kodama, Mei Shimada, Takehisa Kitazawa, Tomoyuki Igawa, Momoko Miura-Okuda, Chie Kato, Junko Shinozuka, Sotaro Naoi, … Gupta Garvita. (2024). SAIL66, a next generation CLDN6-targeting T-cell engager, demonstrates potent antitumor efficacy through dual binding to CD3/CD137. Journal for ImmunoTherapy of Cancer, 12(10). https://doi.org/10.1136/jitc-2024-009563

Chicago

Shu Feng, Hiroyuki Aburatani, Mika Kamata-Sakurai, Shinya Ishii, Takayuki Kamikawa, Naoki Kimura, Masaru Muraoka, et al. 2024. “SAIL66, a next Generation CLDN6-Targeting T-Cell Engager, Demonstrates Potent Antitumor Efficacy through Dual Binding to CD3/CD137.” Journal for ImmunoTherapy of Cancer 12 (10). doi:10.1136/jitc-2024-009563.